
iBio (IBIO) Stock Forecast & Price Target
iBio (IBIO) Analyst Ratings
Bulls say
iBio is a preclinical biotechnology company that leverages the power of Artificial Intelligence (AI) to develop precision antibodies for hard-to-target cancers and other diseases. The company's AI-guided epitope-steering technology and monoclonal antibody optimization reduce downstream risks, making it an attractive target for investors. However, its development stage and lack of revenue-generating products may require future fundraising, which could dilute stock value. Additionally, the company faces significant competition in the biotechnology and pharmaceutical industries. Despite these challenges, iBio's promising potential and innovative platform make it a compelling investment opportunity for those with a longer time horizon.
Bears say
iBio is a relatively early stage biotechnology company with a preclinical pipeline that has yet to generate any revenue. They face significant competition in the biotech and pharma industries and will likely need to raise additional capital in the future. Additionally, there is no guarantee that their intellectual property will sufficiently protect their product candidates, which could lead to potential legal expenses. All of these factors contribute to a negative outlook on iBio's stock.
This aggregate rating is based on analysts' research of iBio and is not a guaranteed prediction by Public.com or investment advice.
iBio (IBIO) Analyst Forecast & Price Prediction
Start investing in iBio (IBIO)
Order type
Buy in
Order amount
Est. shares
0 shares